Davide Martino

Davide Martino

Auto-generated profile, based on publicly available information

Davide Martino

Department of Clinical Neurosciences University of Calgary Calgary AB Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2021 in European Child & Adolescent Psychiatry
Verified
Journal Article
Open access
PDF file
Natalia SzejkoNatalia Szejko
Natalia Szejko
SRSally Robinson
Sally Robinson
AHAndreas Hartmann
Andreas Hartmann
CGChristos Ganos
Christos Ganos
NDNanette Mol Debes
Nanette Mol Debes
DCDanielle C. Cath
Danielle C. Cath
In 2011 a working group of the European Society for the Study of Tourette Syndrome (ESSTS) has developed the first European assessment guidelines for Tourette syndrome (TS). Now, we present an updated version 2.0 of these European clinical guidelines for Tourette syndrome and other tic disorders, part I: assessment. Therefore, the available literature has been thoroughly screened, supplemented with national guidelines across countries and discussions among ESSTS experts. Diagnostic changes between DSM-IV and DSM-5 classifications were taken into account and new information has been added regarding differential diagnoses, with an emphasis on functional movement disorders in both children and adults. Further, recommendations regarding rating scales to evaluate tics, comorbidities, and neuropsychological status are provided. Finally, results from a recently performed survey among ESSTS members on assessment in TS are described. We acknowledge that the Yale Global Tic Severity Scale (YGTSS) is still the gold standard for assessing tics. Recommendations are provided for scales for the assessment of tics and psychiatric comorbidities in patients with TS not only in routine clinical practice, but also in the context of clinical research. Furthermore, assessments supporting the differential diagnosis process are given as well as tests to analyse cognitive abilities, emotional functions and motor skills.

13 August 2021 in Movement Disorders
Verified
Journal Article
Open access
PDF file
TPTamara Pringsheim
Tamara Pringsheim
CGChristos Ganos
Christos Ganos
JMJoseph F. McGuire
Joseph F. McGuire
THTammy Hedderly
Tammy Hedderly
DWDouglas Woods
Douglas Woods
DMDavide Martino
Davide Martino
Click on the article title to read more.

1 January 2017
Verified
Book Chapter
Closed access
DMDavide Martino
Davide Martino
CGChristos Ganos
Christos Ganos
TPTamara M. Pringsheim
Tamara M. Pringsheim

13 January 2023 in European Journal of Neurology
Verified
Journal Article
Closed access
TPTamara Pringsheim
Tamara Pringsheim
CGChristos Ganos
Christos Ganos
CNChristelle Nilles
Christelle Nilles
ACAndrea E. Cavanna
Andrea E. Cavanna
DGDonald L. Gilbert
Donald L. Gilbert
DMDavide Martino
Davide Martino

14 May 2018 in The Canadian Journal of Psychiatry
Verified
Journal Article
Closed access
DMDavide Martino
Davide Martino
VKVikram Karnik
Vikram Karnik
SOSydney Osland
Sydney Osland
TBThomas R. E. Barnes
Thomas R. E. Barnes
TPTamara M. Pringsheim
Tamara M. Pringsheim
Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D2R association rate and serotonin 5-HT2Aantagonism, could contribute to this variation.

4 August 2021 in European Journal of Neurology
Verified
Journal Article
Open access
TPTamara Pringsheim
Tamara Pringsheim
DMDavide Martino
Davide Martino
Background and purpose: Clinicians have reported an increase in functional tic‐like behaviours in children and youth during the COVID‐19 pandemic. We describe adults developing rapid onset of functional tic‐like behaviours between May 2020 and June 2021.Methods: Data were analysed from the Adult Tic Disorders Registry, a single‐site,12‐month prospective cohort study that began enrolment in January 2021. We compared clinical features of participants with Tourette syndrome or persistent motor/vocal tic disorder to participants with rapid onset tic‐like behaviours.Results: Thirty‐three participants registered between January and June of 2021; nine had rapid onset tic‐like behaviours, and 24 had Tourette syndrome or persistent motor tic disorder. Participants with rapid onset tic‐like behaviours were younger (19.9 vs. 38.6 years, p = 0.003), had older age at onset (15.3 vs. 10.1, p = 0.0009), and were more likely female (p < 0.0001). They had higher motor and vocal tic severity and impairment scores (all p < 0.01) and were more likely to have complex arm/hand motor tics (p < 0.0001), complex vocal tics (p < 0.0001), and coprolalia (p = 0.004). They had significantly higher scores on all mental health symptom self‐report measures (all p < 0.05) and were significantly more likely to be diagnosed with depression (p = 0.03).Conclusions: The clinical features that help differentiate rapid onset tic‐like behaviours from Tourette syndrome or persistent motor tic disorder include their phenomenology, onset age, and clinical course. Rapid onset tic‐like behaviours are a distinct subtype of functional neurological disorder that has emerged during the COVID‐19 pandemic in young people and appears to be strongly socially influenced.